Meriofert (Follicle-Stimulating Hormone, Luteinising Hormone)

The FSH component binds to FSH receptors on granulosa cells, promoting follicle growth and estrogen production. The LH component binds to LH receptors on theca and luteal cells, supporting androgen conversion to estrogen and triggering final oocyte maturation and ovulation. Together they mimic the natural hormonal cascade required for successful follicular development.

The dose of Meriofert is individualized by the prescribing physician based on the patient’s ovarian reserve, treatment protocol, and response to therapy. Clinicians determine the amount, frequency, and duration of administration, and adjustments are made according to monitoring of hormonal levels and ultrasound findings.

Meriofert is intended for use before conception to induce ovulation; it is not administered during pregnancy. Its safety in pregnancy has not been established, and it should be discontinued once pregnancy is confirmed. Limited data are available for breastfeeding, and the decision to use the product while nursing should be made by a qualified healthcare professional.

To order Meriofert, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Meriofert combines both FSH and LH in a single injectable formulation, whereas some alternatives provide only FSH or require separate LH supplementation. This dual‑action approach can simplify dosing schedules and may improve follicular response in certain patients, but the choice of therapy depends on individual clinical factors and physician preference.

Meriofert must be stored refrigerated at 2‑8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If the product reaches room temperature, it should be used promptly and not be returned to refrigeration.

Meriofert is supplied as a sterile liquid for injection and is administered either intramuscularly or subcutaneously, as directed by the treating physician. The injection site is typically the abdomen or thigh, and aseptic technique must be followed to reduce the risk of infection.

The most serious risks include severe ovarian hyperstimulation syndrome, which can cause rapid weight gain, abdominal pain, and fluid accumulation; thromboembolic events such as deep‑vein thrombosis; and rare anaphylactic reactions. Patients should be monitored closely for these complications, and treatment should be discontinued if they occur.

Meriofert should not be used in patients with known hypersensitivity to any component of the formulation, active ovarian cysts, uncontrolled thyroid disease, or those who are pregnant. Caution is also advised for individuals with a history of thromboembolic disorders or severe cardiovascular disease, and the decision to treat should be made by a qualified specialist.